| [1] |
Rhiem K, Engel C,Engel J, et al. BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer [J/OL]. J Clin Oncol, 2016, 34(15 suppl):1090[2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/1090? sid=0a5136c3-2664-4077-b579-a62056883315.
|
| [2] |
Vidula N, Yau C, Wolf DM, et al. Androgen receptor (AR)expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes [J/OL]. J Clin Oncol, 2016, 34(15 suppl): 1072 [2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/1072? sid = 934241ec-6fbc-4624-86fd-58429d5df961.
|
| [3] |
Shao ZM, Li JJ, Pang D, et al. Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer [J/OL]. J Clin Oncol, 2016,34(15 suppl): 1012 [2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/1012? sid = aae55a8e-fa44-41b4-b3cf-99ab8678be78.
|
| [4] |
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC):10-year survival results from the randomized FinXX trial [J/OL]. J Clin Oncol, 2016, 34 (15 suppl):1001 [2016-06-10]. http:/ /meeting.ascopubs. org/cgi/content/abstract/34/15_suppl/1001? sid=496b684b-2491-422d-a7e8-7646c75636d2.
|
| [5] |
Joensuu H, Kellokumpu-Lehtinen PL,Huovinen R,et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial [J]. J Clin Oncol,2012,30(1):11-18.
|
| [6] |
Yuan P, Du F, Wang JY, et al. Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T)versus six cycles docetaxel and carboplatin ( TP) as adjuvant chemotherapy for women with operable triple negative breast cancer [J/OL].J Clin Oncol,2016,34(15 suppl):1068[2016-06-10]. http:/ /meeting.ascopubs. org/cgi/content/abstract/34/15_suppl/1068? sid=31ab5b91-8746-411d-ba61-a6e5c55d49af.
|
| [7] |
Takahashi M,Yonemori K,Yamamoto H,et al. A phase Ⅰ/Ⅱtrial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The analyses of efficacy and safety from phase Ⅱ[J/OL].J Clin Oncol,2016,34(15 suppl): 1080[2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15 _suppl/1080? sid=67582b01-a5de-45a7-9c81-31bb1e6f02a7.
|
| [8] |
Brufsky A, Kim SB, Velu TJ, et al. Cobimetinib (C)+paclitaxel (P)as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study [J/OL].J Clin Oncol,2016,34(15 suppl):1074[2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/1074? sid=e53e0f0c-bee2-4446-85c5-4b92f1b09916.
|
| [9] |
Adams S, Diamond JR, Hamilton EP, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC) [J/OL]. J Clin Oncol,2016, 34(15 suppl):1009[2016-06-10]. http:/ /meeting.ascopubs. org/cgi/content/abstract/34/15 _ suppl/1009? sid =ea0f16d5-e998-4447-9e14-5a1b141dc71c.
|
| [10] |
Becerra C, Braiteh FS,Spira AI,et al. A phase Ib/Ⅱstudy of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced triple negative breast cancer [J/OL]. J Clin Oncol,2016,34(15 suppl): 1094[2016-06-10]. http:/ /meeting.ascopubs. org/cgi/content/abstract/34/15 _ suppl/1094? sid =944337ed-8c30-4af5-9bbf-6336622eda04.
|
| [11] |
Tung NM, Garber JE, Hacker MR, et al. Distant recurrences in triple negative breast cancer (TNBC) according to androgen receptor (AR)status [J/OL]. J Clin Oncol,2016,34(15 suppl): 1085[2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15 _suppl/1085? sid=77904a3d-ac56-497a-ab77-c629fdf3e877.
|
| [12] |
Bhattarai S, Xia J, Wetherilt CS, et al. A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers [J/OL]. J Clin Oncol,2016,34(15 suppl): 1089[2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/1089? sid=3389a8e9-0ab6-47ed-8fde-190ae9d38b2d.
|
| [13] |
Afghahi A, Rigdon J, Purington N, et al. Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer(TNBC) [J/OL].J Clin Oncol,2016,34(15 suppl): 1010[2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15 _suppl/1010? sid=4ba93683-b32b-4e2f-8d59-39a0b2f13b7b.
|
| [14] |
Klimov S, Green AR, Aleskandarany M, et al. Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers [J/OL]. J Clin Oncol,2016,34(15 suppl): 1092 [2016-06-10]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/1092? sid= e5869ccc-0cfa-4c74-b90eb6129d61baeb.
|